Insider transactions

EDGAR

DIAMEDICA THERAPEUTICS INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
4 transactions, 450,650 shares
Sum of shares × price per share: 3,443,324.846
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–19 of 19

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-10 Filed 2026-08-12Pauls Dietrich John Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Voting Common Shares, no par value per share
Acquired (A)60,2000—128,791Direct (D) No
F1, F2
  • F1 The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.
  • F2 Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
Open filing 0001760123-26-000004 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Semba Charles Pauling Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (40,412) — exercise price 5.84
Acquired (A)40,4120—40,412Direct (D) No
F1
  • F1 Scheduled to vest in four equal quarterly installments.
Open filing 0001872863-26-000004 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Krop Julie Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (67,500) — exercise price 5.84
Acquired (A)67,5000—67,500Direct (D) No
F1
  • F1 Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.
Open filing 0001643127-26-000002 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Kellen Scott Officer: CFO Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (162,000) — exercise price 5.84
Acquired (A)162,0000—162,000Direct (D) No
F1
  • F1 Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.
Open filing 0001490476-26-000002 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Kuntz Richard Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (40,412) — exercise price 5.84
Acquired (A)40,4120—40,412Direct (D) No
F1
  • F1 Scheduled to vest in four equal quarterly installments.
Open filing 0001341125-26-000002 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Pauls Dietrich John Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (380,000) — exercise price 5.84
Acquired (A)380,0000—380,000Direct (D) No
F1
  • F1 Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.
Open filing 0001760123-26-000002 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Lewis Tanya Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (40,412) — exercise price 5.84
Acquired (A)40,4120—40,412Direct (D) No
F1
  • F1 Scheduled to vest in four equal quarterly installments.
Open filing 0001451038-26-000002 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Parsons James T. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (51,189) — exercise price 5.84
Acquired (A)51,1890—51,189Direct (D) No
F1
  • F1 Scheduled to vest in four substantially equal quarterly installments.
Open filing 0001759855-26-000004 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Giuffre Randall Michael Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (40,412) — exercise price 5.84
Acquired (A)40,4120—40,412Direct (D) No
F1
  • F1 Scheduled to vest in four equal quarterly installments.
Open filing 0001759822-26-000004 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03O'Connor Daniel J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Voting Common Shares (40,412) — exercise price 5.84
Acquired (A)40,4120—40,412Direct (D) No
F1
  • F1 Scheduled to vest in four equal quarterly installments.
Open filing 0001376847-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Giuffre Randall Michael Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,1758.42
51,993.5

Derived: shares × price per share. Exact value 51993.50.

398,587Direct (D) No
F1
  • F1 Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.
Open filing 0001759822-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Semba Charles Pauling Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,3558.42
28,249.1

Derived: shares × price per share. Exact value 28249.10.

47,963Direct (D) No
F1
  • F1 Shares are issuable upon settlement of restricted stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.
Open filing 0001872863-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Parsons James T. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)10,0958.42
84,999.9

Derived: shares × price per share. Exact value 84999.90.

97,949Direct (D) No
F1
  • F1 Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.
Open filing 0001759855-26-000002 Read from the filing’s XML Dispute this row
2025-11-25 Filed 2025-12-08STAHLBERG JAN 10% ownerTRILL AB 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)73,0998.5749
626,816.6151

Derived: shares × price per share. Exact value 626816.6151.

8,825,742Indirect (I) See FootnoteNo
F1
  • F1 These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.
Open filing 0001104659-25-119360 Read from the filing’s XML Dispute this row
2025-11-24 Filed 2025-12-08STAHLBERG JAN 10% ownerTRILL AB 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)40,2537.8931
317,720.9543

Derived: shares × price per share. Exact value 317720.9543.

8,752,643Indirect (I) See FootnoteNo
F1
  • F1 These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.
Open filing 0001104659-25-119360 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-12-08STAHLBERG JAN 10% ownerTRILL AB 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)208,8727.4092
1,547,574.4224

Derived: shares × price per share. Exact value 1547574.4224.

8,712,390Indirect (I) See FootnoteNo
F1
  • F1 These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.
Open filing 0001104659-25-119360 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Parsons James T. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)12,0002.20
26,400

Derived: shares × price per share. Exact value 26400.00.

87,854Direct (D) No
F1
  • F1 Represents the conversion of the exercise price from CAD$ to US$ on the transaction date.
Open filing 0001759855-25-000006 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-25Parsons James T. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Shares (12,000) — exercise price 2.20
Disposed (D)12,0000—0Direct (D) No
F1, F2
  • F1 Represents the conversion of the exercise price from CAD$ to US$ on the transaction date.
  • F2 Fully vested.
Open filing 0001759855-25-000006 Read from the filing’s XML Dispute this row
2025-11-20 Filed 2025-12-08STAHLBERG JAN 10% ownerTRILL AB 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)128,4267.4067
951,212.8542

Derived: shares × price per share. Exact value 951212.8542.

8,503,518Indirect (I) See FootnoteNo
F1
  • F1 These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.
Open filing 0001104659-25-119360 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Dialectic Life Sciences SPV LLC Voting common shares, no par value per share00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-001133 Dispute this row
Dialectic LS Manager LLC Voting common shares, no par value per share00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-001133 Dispute this row
Dialectic Capital Management, LP Voting common shares, no par value per share00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-001133 Dispute this row
Dialectic Partners, LLC Voting common shares, no par value per share00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-001133 Dispute this row
John Fichthorn Voting common shares, no par value per share0.3153,983.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-001133 Dispute this row
Cooperman Leon G. Voting Common Shares, no par value6.63,450,00012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000945621-26-000352 Dispute this row
TRILL AB Common Shares, no par value16.98,825,742.0012/31/2025 Filed 2026-02-06SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-011569 Dispute this row
Jan Stahlberg Common Shares, no par value16.98,825,742.0012/31/2025 Filed 2026-02-06SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-011569 Dispute this row
Richard Jacinto II Voting Common Shares, no par value9.64,958,82309/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 3Open filing 0001193125-25-272616 Dispute this row
Cooperman Leon G. Voting Common Shares, no par value6.33,269,76109/30/2025 Filed 2025-10-15SCHEDULE 13G/AAmendment 1Open filing 0000945621-25-000973 Dispute this row
Trill AB Common Shares, no par value15.027,764,465.0008/14/2025 Filed 2025-09-04SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-087405 Dispute this row
Jan Stahlberg Common Shares, no par value15.027,764,465.0008/14/2025 Filed 2025-09-04SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-087405 Dispute this row
Cooperman Leon G. Voting Common Shares, no par value63,110,22007/23/2025 Filed 2025-08-27SCHEDULE 13GOpen filing 0000945621-25-000820 Dispute this row
Trill AB Common Shares, no par value13.146,764,465.0007/23/2025 Filed 2025-07-30SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-072279 Dispute this row
Jan Stahlberg Common Shares, no par value13.146,764,465.0007/23/2025 Filed 2025-07-30SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-072279 Dispute this row
TomEnterprise AB Common Shares, no par value16.288,383,577.0007/23/2025 Filed 2025-07-30SCHEDULE 13G/AAmendment 4Open filing 0001104659-25-072272 Dispute this row
TomEnterprise Private AB Common Shares, no par value16.288,383,577.0007/23/2025 Filed 2025-07-30SCHEDULE 13G/AAmendment 4Open filing 0001104659-25-072272 Dispute this row
Thomas von Koch Common Shares, no par value16.288,383,577.0007/23/2025 Filed 2025-07-30SCHEDULE 13G/AAmendment 4Open filing 0001104659-25-072272 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,626,574 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201543,661
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to DIAMEDICA THERAPEUTICS INC.